Effect of Nonsteroidal Anti-Inflammatory Drug Restriction on the Efficacy of Platelet-Rich Plasma in Knee Osteoarthritis
Key facts
- Where
- São Paulo, BrazilSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07766330, who can take part
Where in Brazil
- Disciplina de Medicina Esportiva da UNIFESPSão Paulo, BrazilContact: Guilherme Moury Fernandes, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Federal University of São Paulo
- Trial code
- NCT07766330
- Record updated
- 14 August 2026
- Original description
The goal of this randomized clinical trial is to learn whether taking ibuprofen, a nonsteroidal anti-inflammatory drug, after a platelet-rich plasma (PRP) injection changes pain relief and knee function in adults with knee osteoarthritis.Read full original descriptionShow less
The goal of this randomized clinical trial is to learn whether taking ibuprofen, a nonsteroidal anti-inflammatory drug, after a platelet-rich plasma (PRP) injection changes pain relief and knee function in adults with knee osteoarthritis.
The main questions it aims to answer are:
Does ibuprofen change the improvement in knee pain six months after a PRP injection compared with acetaminophen?
Does ibuprofen change knee function or the need for additional pain medicine during follow-up?
Researchers will compare PRP followed by ibuprofen with PRP followed by acetaminophen. Participants will receive one ultrasound-guided PRP injection and take the assigned medication every eight hours for five days. They will complete assessments of pain, knee function, additional pain medicine use, and safety. Participants and the physician performing the injection will not know which medication was assigned.
Inclusion: Age between 18 and 80 years; Knee pain for at least 3 months; Radiographic evidence of knee osteoarthritis classified as Kellgren-Lawrence grade I, II, or III; Ability and willingness to provide written informed consent.
Exclusion: Active or previous oncologic disease, as defined in the protocol; Use of nonsteroidal anti-inflammatory drugs within the previous 30 days; Use of systemic, intra-articular, topical, or inhaled glucocorticoids within the previous 3 months; Current use of anticoagulant or antiplatelet medication; Currently receiving disability or sickness-related social security benefits; Hematologic disease, including anemia, coagulopathy, or thrombophilia; Rheumatologic disease; Chronic kidney disease; Respiratory disease, including rhinitis, asthma, or chronic obstructive pulmonary disease; Psychiatric disorder currently under treatment; Diabetes mellitus with glycated hemoglobin greater than 6.5%; Hemoglobin below 11 g/dL; Platelet count below 150,000/mm3; Body mass index of 35 kg/m2 or higher; Pregnancy or breastfeeding; Hematocrit below 33%; Advanced knee osteoarthritis; Fibromyalgia; Substance dependence, including smoking, harmful alcohol use, or other substance use; American Society of Anesthesiologists physical status classification of 3 or higher; Inability or unwillingness to provide informed consent or complete the required patient-reported outcome measures.